|
HY-P99764-1mg
|
MedChemexpress LLC
|
Odesivimab [CAS 2135632-30-1]
|
|
|
|
|
HY-P99764-10mg
|
MedChemexpress LLC
|
Odesivimab [CAS 2135632-30-1]
|
|
|
|
|
HY-P99764-5mg
|
MedChemexpress LLC
|
Odesivimab [CAS 2135632-30-1]
|
|
|
|
|
HY-P99768-1mg
|
MedChemexpress LLC
|
Olinvacimab [CAS 2095504-49-5]
|
|
|
|
|
HY-P99768-10mg
|
MedChemexpress LLC
|
Olinvacimab [CAS 2095504-49-5]
|
|
|
|
|
HY-P99768-5mg
|
MedChemexpress LLC
|
Olinvacimab [CAS 2095504-49-5]
|
|
|
|
|
HY-P9950-1mg
|
MedChemexpress LLC
|
Omalizumab [CAS 242138-07-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9950-5mg
|
MedChemexpress LLC
|
Omalizumab [CAS 242138-07-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99770-1mg
|
MedChemexpress LLC
|
Omodenbamab [CAS 2241724-48-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99770-10mg
|
MedChemexpress LLC
|
Omodenbamab [CAS 2241724-48-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99770-5mg
|
MedChemexpress LLC
|
Omodenbamab [CAS 2241724-48-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99794-1mg
|
MedChemexpress LLC
|
Osocimab [CAS 2056878-75-0]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99794-10mg
|
MedChemexpress LLC
|
Osocimab [CAS 2056878-75-0]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99794-5mg
|
MedChemexpress LLC
|
Osocimab [CAS 2056878-75-0]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99406-1mg
|
MedChemexpress LLC
|
Petosemtamab [CAS 2213450-26-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99406-10mg
|
MedChemexpress LLC
|
Petosemtamab [CAS 2213450-26-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99406-5mg
|
MedChemexpress LLC
|
Petosemtamab [CAS 2213450-26-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99156-1mg
|
MedChemexpress LLC
|
Relatlimab [CAS 1673516-98-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P99156-10mg
|
MedChemexpress LLC
|
Relatlimab [CAS 1673516-98-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P99156-5mg
|
MedChemexpress LLC
|
Relatlimab [CAS 1673516-98-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P99399-1mg
|
MedChemexpress LLC
|
Semorinemab [CAS 2159141-27-0]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P99399-10mg
|
MedChemexpress LLC
|
Semorinemab [CAS 2159141-27-0]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P99399-5mg
|
MedChemexpress LLC
|
Semorinemab [CAS 2159141-27-0]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P99591-1mg
|
MedChemexpress LLC
|
Sontuzumab [CAS 372075-37-1]
|
|
|
|
|
HY-P99591-10mg
|
MedChemexpress LLC
|
Sontuzumab [CAS 372075-37-1]
|
|
|
|
